… In the following section, we will review the progress toward the translation of PGx knowledge
to clinical practice for CV drugs and the potential barriers to further clinical implementation …

… barriers to pharmacogenomics implementation in pediatric oncology by assessing the
knowledge, attitudes, and practice … the implementation of pharmacogenomics into clinical practice …

… pharmacogenomics are similar to pharmacologic considerations currently used in daily clinical
practice… when trying to use pharmacogenomics to sort out medication issues in a patient …

… Adoption of pharmacogenetic tests in routine clinical practice has been sparse. One major
barrier to clinical implementation is the lack of clear, curated, peer-reviewed pharmacogenetic …

… PGx role in clinical practice is known, however, it has not been widely adopted yet. In this …
the implementation of PGx testing in clinical practice and the key issues associated with it. …

… barrier, since we believe that institutional support and promotion for the use of
pharmacogenomics biomarkers will greatly improve as the influence of the other barriers decline. …

… , we use the term pharmacogenetics to describe the use of … implementation of
pharmacogenetics into clinical practice … Pharmacogenomic clinical trials help overcome the barrier …

… obstacles to implementation, such … clinical implementation at all. This controversy lingered
despite the handful of genomic applications already in clinical practice in 2011, such as use of …

… of pharmacogenomic testing in the clinical setting already, many challenges still remain for
sustainable implementation. … Efforts to address implementation barriers to improve use are …

… Similar problems were found in PMs with the UGT1A1 *28/*28 genotype receiving … Finally,
and this is the most relevant example of the risk of severe clinical problems in patients with …